Using Platelet-rich Plasma to Improve Female Fertility

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of platelet-rich plasma (PRP) injections to treat various conditions affecting female fertility, including premature ovarian insufficiency, intrauterine adhesion, poor ovarian response, repeated implantation failure, and thin endometrium. The study aims to explore the therapeutic effects and potential mechanisms of PRP in addressing these fertility-related issues, which currently lack effective treatments. By focusing on the ovaries and endometrium, the trial seeks to provide a novel approach to enhance reproductive outcomes for women facing these challenges.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Premature ovarian insufficiency: ① Women aged \>18 and \<40 years old; ② Oligomenorrhea or amenorrhea for more than 4 months (excluding pregnancy); ③ Basal follicle stimulating hormone (FSH) \>25IU/L (interval \>4 weeks) at least 2 times, or total antral follicles (AFC) \<5, or anti-Mullerian hormone (AMH) \<1.1ng/mL.
* Poor ovarian response: ① Advanced age (≥40 years) or other risk factors for poor ovarian response; ② Poor ovarian response in previous IVF cycle, with ≤3 oocytes retrieved using conventional protocols; ③ Decreased ovarian reserve (antral follicle count \<5\~7 or anti-Müllerian hormone \<0.5\~1.1 ug/L). Meeting any 2 of the above 3 criteria is sufficient.
* Intrauterine adhesion: ① Diagnosed by hysteroscopy and scored ≥5 points according to the American Fertility Society criteria (1988); ② With symptoms such as reduced menstrual flow amenorrhea, periodic lower abdominal pain, infertility, or recurrent miscarriage; ③ Adult women with the desire to conceive.
* Thin endometium: ①Endometrial thickness \<7mm on ovulation day or on the day of human chorionic gonadotropin (HCG) injection, or \<7mm on progesterone conversion day when using conventional hormone replacement therapy, ②adult women with the desire to comceive.
* Repeated implantation failure: Women under 40 years old who have failed to achieve clinical pregnancy after transplanting at least three high-quality embryos within three fresh or frozen cycles. High-quality embryos include: Day 3 embryos (with ≥8 cells, evenly sized blastomeres, and \<10% fragmentation) and blastocysts (≥3BB).

Exclusion Criteria:

* Alanine aminotransferase \> 3 times the normal upper limit or estimated glomerular filtration rate (EGFR) \< 90 ml/min;
* Suffering from hemorrhagic diseases (such as hemophilia) or taking anticoagulant or antiplatelet drugs;
* Suffering from serious mental illness, cardiovascular and cerebrovascular diseases and malignant tumors;
* Suffering from diabetes with poor blood sugar control or other systemic diseases;
* Drug abuse, alcoholism or drug addiction;
* Participated in other interventional clinical studies within half a year;
* Poor compliance;
* Other circumstances that are not suitable for participating in the study.

Where it's running

• The Fourth Affiliated Hospital of Zhejiang University School of Medicine
  Yiwu, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Youhua Lai
• Email: tj_lyh1@163.com
• Phone: +86 15925977413

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Autologous Hair Follicle Secretome + PRP for POI

  This pilot study tests whether a patient’s own hair follicle secretome combined with their own platelet-rich plasma can improve ovarian function in women with premature ovarian insufficiency.

  Recruiting Phase 2 Trio Fertility · Toronto, Ontario · NCT07916740

• Ovulation Trigger Strategies for Women with Low Ovarian Reserve

  In women with low ovarian reserve undergoing IVF, this study tests three different ovulation-triggering approaches to see if adding follitropin delta can increase mature eggs without hurting pregnancy chances.

  Recruiting Phase 3 Fundación para la Investigación del Hospital Clínico de Valencia · Valencia · NCT07816562

• Intravenous hUC-MSCs for POI: Safety, Tolerability and Early Efficacy

  We’re testing whether IV human umbilical cord mesenchymal stem cells can be safely given to women under 40 with premature ovarian insufficiency to see if it helps improve ovarian function.

  Recruiting Phase 1/2 Shenzhen Wingor Biotechnology Co., Ltd. · Beijing, Beijing Municipality · NCT07775391

• Intrauterine Adhesion Prevention With a Uterine Stent After Surgery

  This trial tests whether placing a uterine stent after adhesion surgery helps prevent repeat adhesions in women aged 20–40 with intrauterine adhesions.

  Recruiting The Third Xiangya Hospital of Central South University · Changsha, Hunan · NCT07611474

• A combined 4D ultrasound, hysteroscopic cold-knife plowing, uterine stent, and traditional Chinese medicine approach for intrauterine adhesions

  This project will try a combined care pathway—preoperative 4D ultrasound, hysteroscopic cold-knife adhesion separation, a postoperative uterine stent, and traditional Chinese medicine—to see if it improves outcomes for women aged 18–45 with intrauterine adhesions.

  Recruiting The Third Xiangya Hospital of Central South University · Changsha, Hunan · NCT07421908

• Proteomic profiling of plasma before and after stem cell mobilization in poor ovarian responders

  This study tests whether stem cell mobilization changes the protein makeup of platelet-rich plasma used in StemCell Regenera for women with poor ovarian response.

  Recruiting Instituto Valenciano de Infertilidad, IVI Alicante · Alicante, Alicante · NCT07376460

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.